Loading clinical trials...

NOT_YET_RECRUITINGPHASE1/PHASE2

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

An Open, Multicenter Phase I/II Trial of SHR-A1921 in Combination With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

NCT06434103•Suzhou Suncadia Biopharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

A trial to evaluate the tolerability and efficacy of SHR-A1921 in combination with adbelizumab and SHR-8068 with or without carboplatin in patients with advanced non-small cell lung cancer

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Volunteer to join the clinical study, and sign the informed consent, compliance is good, can cooperate with follow-up;
•2. Aged 18-75 at the time of signing the informed consent;

Exclusion Criteria

•4. At least one measurable lesion consistent with RECIST v1.1;
•5. ECOG PS score: 0-1;
•6. The organ function level is good;
•1. Untreated (radiation or surgery) central nervous system metastasis, or accompanied by meningeal metastasis, spinal cord compression, etc.;
•2. Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion with clinical symptoms;
•3. Previous or co-existing malignant neoplasms;
•4. The presence of any active or known autoimmune disease;
•5. Have clinical symptoms or diseases of the heart that are not well controlled;
•6. People with past or current interstitial pneumonia/interstitial lung disease;
•7. Known allergic reactions to any component of SHR-A1921, Adebrelimab, or severe allergic reactions to other monoclonal antibodies;
+1 more criteria

Key Dates

Start Date

June 1, 2024

Primary Completion Date

June 1, 2025

Completion Date

March 1, 2027

Last Updated

May 30, 2024

Enrollment

124

ESTIMATED participants

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

SHR-A1921；Adebrelimab；SHR-8068；carboplatin

DRUG

Contacts

Mengbo Zhao

CONTACT

0518-82342973 mengbo.zhao@hengrui.com

Ze Zhang

CONTACT

0518-82342973 ze.zhang.zz1@hengrui.com

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

NCT06731413

Non-Small Cell Lung CancerNSCLC+2 more

View study

RECRUITING

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

NCT07356544

NSCLC (Advanced Non-small Cell Lung Cancer)HER2

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Inclusion Criteria

Exclusion Criteria

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer